Navigation Links
Progentix Orthobiology and NuVasive Sign Investment Agreement
Date:1/14/2009

BILTHOVEN, The Netherlands, January 14 /PRNewswire/ -- Progentix Orthobiology B.V. announced today that it has closed an investment agreement with NuVasive, a medical device company focused on developing products for minimally disruptive surgical treatments for the spine. Under the terms of the agreement NuVasive will gain access to Progentix' synthetic bone substitutes designed to accelerate bone healing through a novel micro-structure created by a proprietary manufacturing process.

NuVasive's initial commitment will be $15 million in cash, consisting of a $10 million equity purchase from Progentix shareholders and a $5 million loan used to fund ongoing clinical and regulatory efforts. Upon accomplishment of the complete set of pre-defined development milestones, NuVasive will be obligated to purchase the remaining equity of Progentix for $45 million, and, upon the achievement of additional milestones and NuVasive's sales success, pay a maximum earn-out of $25 million. In addition, NuVasive obtained exclusive worldwide distribution rights as well as an exclusive option to purchase all of Progentix under certain circumstances.

Joost de Bruijn, PhD, chief executive officer of Progentix Orthobiology said: "We are extremely pleased to be working with NuVasive, a company that has built an impressive track record of growth in the spine market by consistently and successfully leveraging innovation. NuVasive's investment allows Progentix to continue developing its unique family of bone graft materials and allows the near term commercialization of these products."

The Progentix product portfolio currently consists of a novel family of calcium phosphate synthetic bone substitutes. The Progentix granules have demonstrated osteoinductive-like properties in preclinical models and require FDA clearance via a 510(k) pathway. A putty formulation of the product is currently under development. Progentix is a spin-out from Twente University, the Netherlands, and has close ties to Queen Mary University in London, UK, where Mr. de Bruijn is a Professor of Biomaterials and focuses on the research of Progentix' unique suite of biomaterials. Progentix, founded in 2007, obtained a series A financing from BioGeneration Ventures in early 2008, allowing the accelerated development of its groundbreaking technology.

About Progentix Orthobiology

Progentix Orthobiology B.V. was established in 2007 and develops CuriOs (TM), a unique suite of osteoinductive-like material products for clinical application in bone regenerative surgery. CuriOs is based on surface structured ceramic biomaterial scaffolds that, in preclinical testing, have shown the ability to attract stem cells after implantation.

W: http://www.progentix.com


'/>"/>
SOURCE Progentix Orthobiology
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Progentix Orthobiology B.V. Closes Series A Financing Round
2. Nuvasive Reports Third Quarter 2008 Financial Results
3. NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference
4. NuVasive Completes Acquisition of Osteocel Biologics Business
5. NuVasive Announces Web Cast and Conference Call of Second Quarter 2008 Results
6. NuVasive to Present at William Blair 28th Annual Growth Stock Conference
7. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
8. NuVasive to Present at Lehman Brothers Eleventh Annual Global Healthcare Conference
9. NuVasive to Present at Canaccord Adams Small-Cap Orthopedics Conference
10. NuVasive Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results
11. NuVasive to Host Investor Reception on September 11, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Research and Markets has announced the addition of Jain PharmaBiotech,s ... their offering. ... This report describes different types ... proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery ... Currently the most important applications of biomarkers are in drug ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Germany ... AxioMed disc in Cologne and Karlsruhe to discuss the benefits of a viscoelastic ...
(Date:12/5/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... chronic diseases, announced that Catherine Bovenizer , ... Officer (CFO), effective today. Ms. Bovenizer ... in financial management for a variety of public ... recently, Ms. Bovenizer was the Vice President of ...
(Date:12/5/2016)... 5, 2016 NxGen MDx announced today that it brought its ... house, we,ve been able to improve customer service through shortened turnaround times ... Alan Mack , CEO of NxGen MDx. ... , A decrease in turnaround ... to more job opportunities at the Grand Rapid headquarters. The ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/17/2016)... 17, 2016  AIC announces that it has just released a new white paper ... high-performance scale-out plus high speed data transfer storage solutions. Photo - ... ... ... Setting up a high performance computing or HPC ...
Breaking Biology News(10 mins):